Inicio
Detalle del título uniforme
Journal of Global Oncology
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (1)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study / Kenny Mauricio Gálvez Cárdenas
Título : Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2019 Títulos uniformes : Journal of Global Oncology Idioma : Inglés (eng) Resumen : Purpose: Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. Methods: This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). Results: Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Conclusion: The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making. Mención de responsabilidad : Vania Tietsche de Moraes Hungria, Carlos Chiattone, Miguel Pavlovsky, Lina M Abenoza, Gladys P Agreda, Jorge Armenta, Celso Arrais, Oscar Avendaño Flores, Fernando Barroso, Ana L Basquiera, Carmen Cao, Maria S Cugliari, Alicia Enrico, Laura M Foggliatto, Kenny M Galvez, David Gomez, Alvaro Gomez, Daniel de Iracema, Danielle Farias, Lineth Lopez, William Armando Mantilla, Deborah Martínez, Maria Jose Mela, Carlos E Miguel, Roberto Ovilla, Luis Palmer, Carolina Pavlovsky, Christian Ramos, Guillermina Remaggi, Rodrigo Santucci, Sergio Schusterschitz, Claudia Lucia Sossa, Elena Tuna-Aguilar, Jorge Vela, Telma Santos, Odin de la Mora, Gerardo Machnicki, Mariana Fernandez, Paula Barreyro Referencia : J Glob Oncol. 2019;5:1–19. DOI (Digital Object Identifier) : 10.1200/JGO.19.00025 PMID : 31774711 Derechos de uso : CC BY-NC-ND En línea : https://ascopubs.org/doi/full/10.1200/JGO.19.00025 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5080 Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2019.
Obra : Journal of Global Oncology
Idioma : Inglés (eng)
Resumen : Purpose: Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. Methods: This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). Results: Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Conclusion: The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making. Mención de responsabilidad : Vania Tietsche de Moraes Hungria, Carlos Chiattone, Miguel Pavlovsky, Lina M Abenoza, Gladys P Agreda, Jorge Armenta, Celso Arrais, Oscar Avendaño Flores, Fernando Barroso, Ana L Basquiera, Carmen Cao, Maria S Cugliari, Alicia Enrico, Laura M Foggliatto, Kenny M Galvez, David Gomez, Alvaro Gomez, Daniel de Iracema, Danielle Farias, Lineth Lopez, William Armando Mantilla, Deborah Martínez, Maria Jose Mela, Carlos E Miguel, Roberto Ovilla, Luis Palmer, Carolina Pavlovsky, Christian Ramos, Guillermina Remaggi, Rodrigo Santucci, Sergio Schusterschitz, Claudia Lucia Sossa, Elena Tuna-Aguilar, Jorge Vela, Telma Santos, Odin de la Mora, Gerardo Machnicki, Mariana Fernandez, Paula Barreyro Referencia : J Glob Oncol. 2019;5:1–19. DOI (Digital Object Identifier) : 10.1200/JGO.19.00025 PMID : 31774711 Derechos de uso : CC BY-NC-ND En línea : https://ascopubs.org/doi/full/10.1200/JGO.19.00025 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5080 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001310 AC-2020-014 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-014.pdfAdobe Acrobat PDF